Gregory M. Glenn

President, Research & Development at Novavax, Inc.

Gregory M. Glenn

Gregory M. Glenn

President, Research & Development at Novavax, Inc.

Overview

Career Highlights

Intercell USA, Inc.

RelSci Relationships

196

Birthday

1954

Age

67

Number of Awards

1

Contact Data

Trying to get in touch with Gregory M. Glenn? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!

Relationships

View Relationship Details

RelSci Relationships are individuals Gregory M. Glenn likely has professional access to. A relationship does not necessarily indicate a personal connection.

Rip Wilson

General Counsel at Intercell USA, Inc.

Relationship likelihood: Strong

Stanley C. Erck

President & Chief Executive Officer at Novavax, Inc.

Relationship likelihood: Strong

Katherine Cohen

Co-Founder at Hookipa Pharma, Inc.

Relationship likelihood: Strong

Richard Tilton Kenney

Vice President, Medical & Regulatory Affairs at Intercell USA, Inc.

Relationship likelihood: Strong

John A. Herrmann III

Executive Vice President, Chief Legal Officer & Corporate Secretary at Novavax, Inc.

Relationship likelihood: Strong

Jill Hoyt

Executive Vice President & Chief Human Resources Officer at Novavax, Inc.

Relationship likelihood: Strong

Reinhard Kandera

Chief Accounting Officer, Chief Financial Officer & Director at Hookipa Pharma, Inc.

Relationship likelihood: Strong

Mervyn L. Hamer

Vice President, Operations at Intercell USA, Inc.

Relationship likelihood: Strong

Thomas Lingelbach

Co-President & Chief Executive Officer at Valneva SE

Relationship likelihood: Strong

Denise Giangola Courbron

Former Executive Director, Global Program Management at Novavax, Inc.

Relationship likelihood: Strong

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.

In The News

CNN

April 1, 2021

How the Novavax Covid-19 vaccine works

The New York Times

March 13, 2021

In a Crucial South African Vaccine Trial, a Cautionary Tale

Time Magazine

March 11, 2021

Novavax Reports Its COVID-19 Vaccine is 96% Efficacious, Based on Phase 3 Trial Results

RelSci

March 8, 2021

Gregory M. Glenn sold $1.51M worth of shares in Novavax, Inc. in February 2021

GlobeNewswire

March 8, 2021

Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat

Paths to Gregory M. Glenn

Potential Connections via
Relationship Science

You

Gregory M. Glenn

President, Research & Development at Novavax, Inc.

Education

Doctor of Medicine Degree

Oral Roberts University

To develop Holy Spirit-empowered leaders through whole person education to impact the world.

Bachelor of Arts Degree in Biology & Chemistry

Whitman College

Whitman College is renowned for combining academic excellence, an unpretentious Northwest culture, and an engaging community. We are honored to attract students who represent the Whitman mosaic – down-to-earth, high achievers with diverse interests. We are proud of our campus and the diversity and accomplishments of our students, staff, and faculty. A Whitman education liberates minds, inspires spirit and unleashes imagination. It fosters relationships that last a lifetime. We value community – on campus and off. Whitman holds dear the traditions and value of a liberal arts education, yet the college continually evolves itself to ensure that graduates are prepared for futures that offer limitless possibilities.

Career History

President, Research & Development

2010 - Current

Novavax, Inc.

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Founder

1997 - 2008

Intercell USA, Inc.

Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD.

Chief Scientific Officer

2008 - Prior

Intercell AG

Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria.

Investments

Details Hidden

Intercell USA, Inc.

Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD.

Public Holdings

Restricted data only for RelSci Professional users.

Awards & Honors

American Board of Pediatrics - Board Certified Pediatrician

Other Affiliations

Gregory M. Glenn is affiliated with Novavax, Inc., Intercell USA, Inc., Intercell AG, Walter Reed Army Institute of Research, Johns Hopkins Bloomberg School of Public Health

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Gregory M. Glenn. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Gregory M. Glenn's profile does not indicate a business or promotional relationship of any kind between RelSci and Gregory M. Glenn.